Search
Epratuzumab
go.drugbank.com/drugs/DB04958InvestigationalEpratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2).
Bectumomab
go.drugbank.com/drugs/DB04962ExperimentalBectumomab (marketed under the trade name LymphoScan®) is a mouse monoclonal antibody and which it's used to treat non-Hodgkin's lymphoma. It has a radioisotope, technetium (99m TC) which it's added.
Lesopitron
go.drugbank.com/drugs/DB04970ExperimentalLesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.
Rimiducid
go.drugbank.com/drugs/DB04974InvestigationalRimiducid is a lipid-permeable tacrolimus analogue and a protein dimerizer.
Tigapotide
go.drugbank.com/drugs/DB04985InvestigationalTigapotide is a synthetic 15-mer peptide that is derived from the natural sequence of amino acids of the prostate secretory protein (PSP94), one of three predominant proteins found in human seminal fluid
Ty800
go.drugbank.com/drugs/DB04989InvestigationalTy800 is a vaccine designed to offer rapid, oral, single-dose protection against <i>Salmonella typhi</i>, the cause of typhoid fever.
Adecatumumab
go.drugbank.com/drugs/DB05006InvestigationalAdecatumumab is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM). … EpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer.
SGS-742
go.drugbank.com/drugs/DB05010InvestigationalSGS-742 has been used in trials studying the treatment of Seizures and Metabolic Disease.
Categories: Compounds used in a research, industrial, or household settingXL999
go.drugbank.com/drugs/DB05014InvestigationalXL999 induces a cell-cycle block by a mechanism distinct from those previously identified and exhibits broad antitumor activity in xenograft models. … XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic properties, including FGFR 1/3, PDGFRα/β, VEGFR2/KDR, KIT, and FLT3.
Ataluren
go.drugbank.com/drugs/DB05016ApprovedWithdrawnAtaluren is a novel, orally administered drug that targets nonsense mutations. … More specifically, ataluren is used in the small group of patients whose disease is caused by a specific genetic defect (called a ‘nonsense mutation’) in the dystrophin gene.